Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04866069
Other study ID # ISV2AOH3ODN
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date April 25, 2021
Est. completion date September 5, 2021

Study information

Verified date April 2023
Source The Scientific and Technological Research Council of Turkey
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I study is designed as double-blinded, randomised, placebo controlled, three-armed study composed of two different dose arms of protective adjuvanted inactivated vaccine against SARS-CoV-2 in dose escalations (first low dose group, followed by high dose group) and placebo arm.


Description:

This phase I study is designed as double-blinded, randomised, placebo controlled, three-armed study composed of two different dose arms of protective adjuvanted inactivated vaccine against SARS-CoV-2 in dose escalations (first low dose group, followed by high dose group) and placebo arm. Each dose of vaccine will be defined as a cohort in itself, with vaccine administration to 20 participants and placebo administration to 5 participants. After completion of low-dose group, decision of switch to high-dose will be taken by the Independent Data Monitoring Committee and will continue accordingly. In the study, 50 healthy participants of 18-45 years of age will be recruited. All injections will be done subcutaneously. Injections will be administered at 1 and 21 days. The participants will be followed for 6 months and the study will be completed in 12 months.


Recruitment information / eligibility

Status Terminated
Enrollment 50
Est. completion date September 5, 2021
Est. primary completion date September 5, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: To be eligible for the study, each participant must satisfy all the following criteria: 1. Healthy participants between 18-45 years of age, 2. Sign an informed consent document, 3. Negative immunoglobulin G (IgG) and immunoglobulin M (IgM) antibody for COVID-19, 4. Negative quantitative polymerase chain reaction (qPCR) SARS-CoV-2 results of nasopharyngeal/sputum samples, 5. Able to comply with the study protocol during the study period, 6. Negative tests for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), 7. Body temperature <37.2 C and no signs of active infection, 8. Body mass index 18-35 kg/m2, 9. Normal laboratory levels of whole blood count, alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin, urea, creatinine, and fasting blood glucose, or abnormal finding detected in any laboratory parameter which is not greater than Grade 1 according to the investigator's evaluation, 10. Good general health (no known disease in the history and physical examination within 14 days prior to the enrolment), 11. Female and male participants who will be able to have appropriate contraception methods within 30 days prior to vaccine injection and within 6 months after vaccination, Exclusion Criteria: Participants with any of the following criteria will be excluded: 1. History of seizure, encephalopathy, or psychosis, 2. History of allergic reactions to any known vaccine or to any component of the study vaccine, 3. Pregnant, breastfeeding, or positive pregnancy test or planning to conceive within 6 months, 4. History of SARS-CoV-2 infection, 5. Severe cardiovascular disorders (arrhythmia, conduction disorders, history of myocardial infarction, uncontrolled hypertension), 6. Severe chronic disorders (asthma, diabetes mellitus, thyroid disorders…etc), 7. Congenital or acquired angioedema, 8. Diagnosis of immunodeficiency, 9. Diagnosis of bleeding diathesis, 10. Use of immunosuppressive treatment, anti-allergic treatment, cytotoxic treatment, inhaler corticosteroids (allergic rhinitis or topical steroid ointments are excluded), 11. Those who received blood and blood product transfusions in the last 6 months, 12. Those on any vaccine program or experimental medication within 1 month prior to the study, 13. History of any vaccination against SARS-CoV-2 within 1 month prior to the study, 14. Use of active tuberculosis treatment, 15. History of addictive drug use, 16. History of alcohol abuse and/or history of alcohol intake more than 2 units per day or 10 units per week and/or positive breath alcohol test (one unit of alcohol equals to 250 mL beer, 125 mL wine or 25 mL whiskey), 17. According to the investigator's evaluation, those who have any condition (medical, psychological, social, etc.) that may impair the patient's compliance with the study will be excluded from the study.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
SARS-CoV-2 vaccine
Adjuvanted inactivated vaccine
Placebo
0.9% NaCl

Locations

Country Name City State
Turkey Ankara City Hospital Phase I Drug Research Center Ankara

Sponsors (4)

Lead Sponsor Collaborator
Osman ERGANIS, PhD, Prof MonitorCRO, The Scientific and Technological Research Council of Turkey, VETAL Inc.

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acute adverse events (AEs) Frequency of acute adverse events in all dosage groups 24 hours
Primary Solicited local and systemic adverse events (AEs) Frequency of local and systemic AEs in all dosage groups 15 days
Primary Unsolicited local and systemic adverse events (AEs) Frequency of local and systemic AEs in all dosage groups 28 days
Secondary Neutralizing antibody response Immunogenicity response by measuring neutralizing antibody titer (anti-spike and anti-RBD) developed against SARS-CoV-2 (by ELISA) Before first dose administration, on Day 21-28-35 and Month 3 and Month 6 after first dose administration.
Secondary Cellular immune response Interferon-? (IFN-?) positive cell level (by ELISPOT) Before first dose administration, on Day 21-28-35 and Month 3 and Month 6 after first dose administration.
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3